Kabiven

Valine, the active ingredient in Kabiven, is a parenteral nutrition presented as a solution for injection for intravenous use. It provides a balanced mixture of essential amino acids to support protein synthesis and maintain nitrogen balance in patients who cannot receive enteral feeding, such as those postoperative, trauma, or critically ill.

GNH USA supplies Kabiven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Kabiven is employed in parenteral nutrition to meet protein and nitrogen requirements across several clinical scenarios.

- Patients unable to receive enteral feeding: supplies essential amino acids to sustain nutrition. - Post‑operative, trauma or critically ill patients: supports recovery by providing building blocks for tissue repair. - Catabolic states: helps maintain nitrogen balance and prevents muscle wasting.

Kabiven may be associated with infusion‑related and metabolic adverse reactions.

Common Side Effects: - Phlebitis or infusion site erythema - Mild hypernatremia - Transient metabolic alkalosis - Elevated serum urea nitrogen - Mild hyperglycemia - Temporary increase in serum triglycerides

Serious or Rare Side Effects: - Hypersensitivity reactions including anaphylaxis - Severe electrolyte disturbances (e.g., hyperkalemia, hypocalcemia) - Hyperammonemia - Acute renal insufficiency - Severe metabolic acidosis - Pulmonary edema from fluid overload

When using Kabiven, clinicians should observe several safety measures.

- Assess renal function: adjust infusion rate in renal impairment. - Monitor electrolytes: check serum levels regularly during therapy. - Evaluate hepatic status: consider reduced clearance in liver disease. - Use aseptic technique: prevent contamination of the intravenous line. - Avoid in patients with known hypersensitivity to any component of the solution. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kabiven can interact with other therapies; awareness of the interaction level guides management.

Major Interactions (Avoid): - Concurrent high‑dose amino acid solutions: may cause osmolar overload and fluid imbalance. - Co‑administration with nephrotoxic drugs: can exacerbate renal stress.

Moderate Interactions (Monitor Closely): - Insulin therapy: amino acids may affect glucose control, requiring dose adjustments. - Diuretics: may alter electrolyte balance, necessitating close monitoring. - Other parenteral nutrition components: compatibility testing is recommended to prevent precipitation.